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AbstrACt
Objectives The predictive ability of the STarT Back Tool 
(SBT) has not yet been examined among acute/subacute 
back and/or neck pain in a primary care setting in respect 
to health-related quality of life (HRQoL) and work ability 
outcomes. The aim of this study was to evaluate the SBT’s 
predictive validity for HRQoL and work ability outcomes at 
long-term follow-up in a population with acute/subacute 
back and/or neck pain.
setting Prospective data from 35 primary care centres in 
south Sweden during 2013.
Participants Patients (n=329) with acute/subacute 
back and/or neck pain, aged 18–67 years, not on sick 
leave or <60 days of sick leave completed the SBT when 
applying for physiotherapy treatment. Long-term follow-up 
measures (median 13 months, range 11–27 months) of 
HRQoL (EQ-5D) and work ability (Work Ability Score) was 
completed by 238 patients (72%).
Outcomes The predictive ability of the SBT for HRQoL and 
work ability outcomes was examined using Kruskal-Wallis 
test, logistic regression and area under the curve (AUC).
results Based on SBT risk group stratification, 103 
(43%), 107 (45%) and 28 (12%) patients were considered 
as low, medium and at high risk, respectively. There were 
statistically significant differences in HRQoL (p<0.001) 
and work ability (p<0.001) at follow-up between all three 
SBT risk groups. Patients in the high risk group had a 
significantly increased risk of having poor HRQoL (OR 6.16, 
95% CI 1.50 to 25.26) and poor work ability (OR 5.08, 95% 
CI 1.75 to 14.71) vs the low risk group at follow-up. The 
AUC was 0.73 (95% CI 0.61 to 0.84) for HRQoL and 0.68 
(95% CI 0.61 to 0.76) for work ability.
Conclusions The SBT is an appropriate tool for identifying 
patients with a poor long-term HRQoL and/or work ability 
outcome in a population with acute/subacute back and/
or neck pain, and maybe a useful adjunct to primary care 
physiotherapy assessment and practice.
trial registration number NCT02609750; Results.
IntrOduCtIOn 
Musculoskeletal pain, especially back pain 
(BP) and neck pain (NP) are highly prevalent 
in the general population1 2 causing disability 
for the individual and high costs for society.3–5 
Individuals with BP and NP are mostly 
managed in primary care6 7 and patients 
presenting with these conditions are at risk 
of sickness absence8 and poor health-re-
lated quality of life (HRQoL).9 10 To have 
concurrent BP and NP is also common11 and 
increases the risk of work disability further 
in the long-term.12 While most individuals 
with acute BP improve quickly and return 
to work,13 for some of them the pain is more 
severe and lasts for a longer period.14 15 In a 
Swedish cohort of individuals with BP and NP, 
about half of the population reported pain 
and disability 5 years after onset.16 There are 
recommendations for the use of screening 
methods in healthcare to identify patients in 
early stages with the purpose to guide them 
to the best treatment,17–19 to support staying 
at work or for enhancing return to work.20 21 
The UK National Institute for Health and 
Care Excellence guidance recommend 
strengths and limitations of this study
 ► This is the first study to evaluate the predictive 
validity of STarT Back Tool (SBT) of the outcomes 
health-related quality of life and work ability at long-
term follow-up in a population with acute/subacute 
back and/or neck pain.
 ► In this prospective study, we have recruited patients 
from 35 different primary care centres, where many 
physiotherapists were engaged.
 ► The predictive validity of the SBT was examined in 
different ways.
 ► Limited baseline data were available for one part of 
the study population.
 ► Limitations of the study were the broad variation in 
time to follow-up.
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using brief questionnaires to identify individuals of poor 
outcomes and stratify care,22 but there is a lack of such 
tools that can be used in primary care. The widely used 
STarT Back Tool (SBT)23 is a brief risk stratification tool 
that includes nine questions on predictors for long-term 
disabling BP, in order to match individuals to appro-
priate targeted treatments, according to their prognostic 
profile. Using the SBT together with targeted treatment 
pathways has shown improved efficiency regarding 
patients’ clinical outcomes and reduced healthcare costs 
in the UK.24 The SBT is cross-culturally adapted and vali-
dated in Swedish25 and recently also for a population with 
both BP and NP in primary care.26 The SBT is developed 
and validated to predict future disability due to low BP 
of any duration,23 27–30 but it has not yet been studied for 
the outcomes of HRQoL and work ability for a popula-
tion with acute/subacute BP and NP in primary care. The 
aim of this study was therefore to evaluate the predic-
tive validity of SBT of the outcomes HRQoL and work 
ability at long-term follow-up in a population with acute/
subacute BP and/or NP. 
MethOds
design
We conducted a prospective psychometric validation 
study with long-term follow-up. The sample was iden-
tified in connection to a randomised clinical trial 
(RCT) in a primary care setting ( ClinicalTrials. gov ID: 
NCT02609750).
Participants and procedure
Participants were consecutively recruited between January 
2013 and January 2014 from 35 primary care centres 
in the southern parts of Sweden, as part of an RCT.31 
Patients who all applied for physiotherapy treatment on 
self-referral due to an episode of acute/subacute (<12 
weeks) BP and/or NP, who were not currently on sick 
leave or had been on sick leave for <60 days and who had 
been working ≥4 consecutive weeks last year were asked 
to participate. It could be either a first episode or a recur-
rent episode of BP and/or NP after a period of at least 
3 months of no substantial pain. Patients who were preg-
nant, had severe pathology (‘red flags’)32 or were not able 
to understand the Swedish language were not eligible to 
participate. At baseline, patients completed the ‘ÖMPSQ-
short’,33 which was used for screening for inclusion to the 
RCT (≥40 points)31 and the SBT, which was administered 
only for the purpose of psychometric testing. Thereafter, 
the SBT was not actively used by the physiotherapists or 
any other professionals. In all, 329 patients completed 
the SBT questionnaire and formed the population of this 
psychometric study. Patients who were older than 67 years 
or younger than 18 years (n=3), declined participation 
(n=4), had any missing item on the SBT (n=11) or those 
who were lost to follow-up (n=73) were excluded. The final 
study population (n=238) consisted of patients included 
in the RCT (RCT intervention, n=61 and RCT control, 
n=99) and patients not included in the RCT (n=78). The 
analyses were restricted to those who had complete data 
for work ability (n=235) and HRQoL (n=238) outcomes 
at long-term follow-up. The reason we included both RCT 
and not RCT patients was to ensure as broad a sample 
as possible for this SBT predictive validity study. RCT 
patients received either structured physiotherapy treat-
ment with a workplace intervention (RCT intervention) 
or structured physiotherapy without a workplace inter-
vention (RCT control)31 and were followed up at the 
planned 12 months follow-up. Not RCT patients received 
usual primary care and were followed up by postal ques-
tionnaires. Data from all questionnaires were manually 
entered into a SPSS V.22.0 database and were thoroughly 
checked and validated. All questionnaires were scored, 
and missing items handled, according to the methods 
specified by the instrument developers.
baseline data
Baseline questionnaire data included type of treatment 
received (RCT intervention, RCT control or usual 
primary care) and self-reports of SBT, age and gender.
STarT Back Tool
The SBT is a 9-item questionnaire with questions relating 
to modifiable physical (item 1–4) and psychosocial (item 
5–9) risk factors for long-term disabling BP, designed to 
support clinicians in directing individuals to different 
levels of care.23 The SBT has three risk subgroups which 
classifies patients into low, medium or high risk for 
poor disability outcomes. The SBT overall score ranges 
between 0 and 9. Item 1–4 is about referred leg pain, neck 
or shoulder pain, difficulties in walking and difficulties 
in dressing. Item 5–9 form the psychosocial subscale, 
which screen for fear of physical activity, anxiety, pain 
catastrophising, depressive mood and overall impact 
from their BP. Items 1–8 have a dichotomous response 
option; ‘disagree’ (0 p) or ‘agree’ (1 p). Item 9 uses a 
5-point Likert scale from ‘not at all’ to ‘extremely’, where 
responses ‘very much’ or ‘extremely’ are counted as 
one point and the other responses as zero. A total score 
of ≤3 points indicates low risk, a total score ≥4 points in 
combination with <4 points on the psychosocial subscale 
(item 5–9) are medium risk and a psychosocial subscale 
score of ≥4 points indicates high risk for poor disability 
outcomes.23
Long-term follow-up data
Health-related quality of life
HRQoL was measured by the EuroQol five-dimension 
(EQ-5D, 3 L) questionnaire,34 which is a generic, HRQoL 
instrument.35 36 The EQ-5D comprises the EQ descrip-
tive system which has five dimensions: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. 
The digits for the five dimensions are combined in a 
5-digit number describing the respondent’s health state.37 
The 5-digit number is given a value between −0.59 and 
1.0 according to the UK tariff,38 where 1 corresponds to 
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full health and lower EQ-5D values reflect lower HRQoL. 
HRQoL was also dichotomised into ‘poor’ HRQoL 
(EQ-5D<0.6) and ‘good’ HRQoL (EQ-5D≥0.6), based on 
a proposed cut-off for having sufficient capacity to be able 
to work for a population with BP and NP.39
Work ability
Work ability was measured by self-reports on the single 
item question (‘current work ability compared with the 
lifetime best’) from the Work Ability Index (WAI).40 41 
This first item in the WAI is known as the ‘Work Ability 
Score’ (WAS).42 It consists of a scale from 0 representing 
‘cannot work at all right now’ to 10 representing ‘my work 
ability as at its best right now’ and has been proposed to 
be used as a simple indicator for assessing the status and 
progress of work ability.43 44 Work ability was also dichot-
omised using a previously published cut-off score43 into 
‘poor’ work ability (WAS <8 points) and ‘good’ work 
ability (WAS ≥8 points).
statistical analyses
SPSS V.22.0 was used for all analyses. We used a non-para-
metric approach which was chosen based on the distribu-
tion of the data. Descriptive data on the study population 
was presented for the total population and for each SBT 
risk group. We separately evaluated the SBT-specific risk 
groups and also the SBT overall score.
Predictive performance of the SBT
First, cross-tabulations were used to describe the propor-
tion of participants in each SBT risk group that had poor 
outcome in long-term follow-up for each outcome. The 
Kruskal-Wallis test was used to study if there were any 
differences between the SBT risk groups on follow-up 
data on HRQoL and work ability (median), respectively. 
Potential differences were confirmed with Mann-Whitney 
U test. Χ2 test for trend was used to confirm potential 
differences concerning poor or good HRQoL and work 
ability.
Second, we calculated the ORs (95% CIs) for SBT risk 
groups to predict poor HRQoL (EQ-5D<0.6) and poor 
work ability (WAS<8) using binary logistic regression. 
Independent variables age, sex, treatment group and time 
to follow-up were also included in the analysis. We built a 
multiple logistic model where all independent variables 
were entered together with the SBT risk groups. For SBT, 
we used the SBT low risk group as the reference group and 
for treatment groups (RCT intervention n=61, RCT control 
n=99, not RCT n=78), we used the ‘not RCT group’ as the 
reference group. The significance level was set at 5%.
Third, we evaluated the ability of the SBT overall 
scores (0–9 points) to discriminate between individuals 
with poor or good HRQoL/work ability in long-term 
follow-up. For that purpose, we used the area under 
the curve (AUC) statistics from receiver operating char-
acteristic (ROC) curves.45 The strength of discrimi-
nation was set according to the following descriptors: 
0.7 to <0.8 acceptable discrimination, 0.8 to <0.9 excellent 
discrimination, and ≥0.9 outstanding discrimination.46
In addition, the predictive validity of the SBT risk 
group cut-offs (low/medium and medium/high) was 
assessed by calculating sensitivity, specificity, positive 
predictive values (PPV), negative predictive values (NPV) 
and positive and negative likelihood ratios (LRs) against 
long-term HRQoL and work ability outcomes. The SBT 
risk group cut-offs (low/medium and medium/high) 
were used in line with the original study.23 The PPV is 
the probability that a poor outcome is present when the 
test is positive and the NPV is the probability that a good 
outcome is present when the test is negative. Higher posi-
tive LRs and lower negative LRs indicate better discrimi-
nation. LRs  >5 or <0.2 are generally seen as supporting 
a strong test, whereas values close to 1 indicate poor test 
performance.47
Patient and public involvement
Relevant patient organisations were involved in the devel-
opment and design of the RCT, where this study was 
embedded. For this psychometric study, no patients were 
involved. The results of this study will be disseminated to 
study participants by the use of SBT in primary care.
ethics
Prior to inclusion, all patients obtained written informa-
tion about the purpose of the study and each individual 
gave informed consent to participate in the study (opt-
out). The principles of the Declarations of Helsinki were 
followed.
resuLts
study population
The inclusion and exclusion of participants in the study is 
presented in a flow chart (figure 1).
The final sample consisted of 238/329 patients (72%) 
including 160 (67%) females and 78 (33%) males. 
Baseline characteristics of the study population are 
summarised in table 1. The patient sample included 103 
(43%) patients at low risk, 107 (45%) patients at medium 
risk and 28 (12%) patients at high risk. The median time 
to long-term follow-up was 13 (range 11–27) months. For 
RCT patients, the median time to follow-up was 12 months 
(range 11–19) and for not RCT patients, the median time 
was 22 months (range 16–27).
Predictive performance of the sbt
There were statistically significant differences in the 
distribution of HRQoL scores (n=238) between the SBT 
low, medium and high risk groups at long-term follow-up 
(p<0.001) and the proportion of patients with poor 
HRQoL (EQ-5D<0.6) was significantly higher in higher 
risk groups (low risk 4%, medium risk 11%, high risk 
36%) (p<0.001) (table 2). We also found differences in 
the distribution of work ability (WAS) scores (n=235) 
between the SBT low, medium and high risk groups at 
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long-term follow-up (p<0.001) and the proportion of 
patients with poor work ability (WAS <8) was significantly 
higher in higher risk groups (low risk 22%, medium risk 
35%, high risk 68%) (p<0.001) (table 2).
The regression analysis showed that the SBT high risk 
group could significantly predict poor HRQoL (OR 6.16, 
95% CI 1.50 to 25.26, B=1.82, p=0.012) and poor work 
ability (OR 5.08, 95% CI 1.75 to 14.71, B=1.62, p=0.003) 
at long-term follow-up also after adjusting for age, sex, 
treatment and time to follow-up (table 3). Our regression 
model was well adapted to the data material as a non-sig-
nificant p value >0.05 of the test by Hosmer and Leme-
show indicates that the model is good48 (table 3).
Regarding the ability of the SBT total scores (0–9 
points) to discriminate between individuals with poor or 
good HRQoL at long-term follow-up, the AUC was 0.73 
(95% CI 0.61 to 0.84), which was ‘acceptable’ (≥0.7) 
(figure 2). For work ability, the AUC was 0.68 (95% CI 
0.61 to 0.76), which was just below the limit (≥7) for 
acceptable discrimination (figure 3).
The sensitivity, specificity, PPV, NPV and LRs for the SBT 
risk groups for HRQoL and work ability are presented in 
table 4. The LRs+ were higher and the LRs− were lower for 
HRQoL outcomes compared with work ability outcomes 
which indicate better discrimination of the SBT for poor 
HRQoL compared with poor work ability (table 3).
dIsCussIOn And COnCLusIOns
This is the first study to evaluate the predictive validity of 
SBT for HRQoL and work ability outcomes at long-term 
follow-up in a population with acute/subacute BP and/
or NP. The findings of this study support the ability of 
the SBT risk groups to predict future poor HRQoL or 
poor work ability, for patients presenting with an episode 
of acute/subacute BP and/or NP in primary care. Indi-
viduals classified as SBT high risk had a significantly 
increased risk of having poor HRQoL (OR 6.2) and 
poor work ability (OR 5.1) in the long-term compared 
with individuals classified as SBT low risk. The popula-
tion studied was relatively homogenous including only 
patients with acute or subacute pain, not individuals with 
chronic pain. This study population differs from the orig-
inal UK development population for SBT by excluding 
chronic BP and including NP. As might be expected, 
Figure 1 Flow chart of inclusion and exclusion of 
participants. EQ-5D, EuroQol five-dimension; SBT, STarT 
Back Tool; WAS, Work Ability Score. 
Table 1 Baseline characteristics of the study population—total population and stratified by SBT risk groups
Variable
Total population
n=238
SBT risk group
Low Medium High
n=103 (43%) n=107 (45%) n=28 (12%)
Age, median (range) 46 (19–67) 45 (22–64) 47 (21–67) 38 (19–63)
Sex, n (%) female 160 (67) 73 (71) 72 (67) 15 (54)
Area of pain*
  BP, n (%) 91 (38) 42 (41) 41 (38) 8 (29)
  NP+BP†, n (%) 147 (62) 61 (59) 66 (62) 20 (71)
Type of intervention, n (%)
  RCT control 99 (41) 21 (20) 60 (56) 18 (64)
  RCT intervention 61 (26) 21 (20) 31 (29) 9 (32)
  Not RCT 78 (33) 61 (60) 16 (15) 1 (4)
*Area of pain based on question number 2 (NP or shoulder pain) on SBT.
†NP+BP patients with neck or shoulder pain with or without back pain.
BP, back pain; NP, neck pain; RCT, randomised clinical trial; SBT, STarT Back Tool.
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the distribution between the SBT risk groups at baseline 
differed compared with the UK development popula-
tion.23 In our study population, the percentage of indi-
viduals at high risk was lower (12%) compared with the 
original UK sample (15%),23 which may be due to our 
sample including patients with acute/subacute pain. 
However, there is still a clear and statistically significant 
difference in HRQoL and work ability outcomes between 
the three risk groups in the expected direction in our 
Swedish sample.
Strengths of this study include the prospective design 
of a well-characterised group of individuals from 35 
different primary care centres. The SBT was used and 
administered by many different physiotherapists which 
makes this setting real and clinically relevant. Another 
strength is that we analysed the predictive validity in 
different ways, for example, we studied both the estab-
lished SBT risk groups and the SBT overall score to 
predict the outcomes of HRQoL and work ability. We 
also analysed the outcomes HRQoL and work ability both 
on the continuous scale (Kruskal-Wallis) and as dichoto-
mised (logistic regression).
A weakness of this study is that we had limited access 
to baseline data from patients not included in the RCT 
(n=78/238) compared with RCT patients (n=160/238). 
For not RCT patients, we did not have access to baseline 
data from HRQoL and work ability questionnaires. For 
that reason, we were not able to do comparative analyses 
Table 3 The ability of the SBT risk groups to predict poor HRQoL* and poor work ability† at long-term follow-up
Coefficient
HRQoL Work ability
OR 95% CI for OR P values OR 95% CI for OR P values
SBT low risk group (ref) 1 1
SBT medium risk group 1.814 0.506 to 6.509 0.361 1.361 0.684 0.380
SBT high risk group 6.160 1.502 to 25.264 0.012 5.075 1.751 to 14.705 0.003
Treatment not RCT (ref) 1 1
Treatment RCT control 1.411 0.073 to 27.252 0.820 7.631 1.284 to 45.341 0.025
Treatment RCT intervention 2.932 0.183 to 47.073 0.448 8.156 1.485 to 44.803 0.016
Time to follow-up (months) 0.949 0.734 to 1.227 0.688 1.146 0.983 to 1.336 0.081
Age (years) 0.984 0.947 to 1.022 0.403 1.014 0.988 to 1.040 0.306
Sex, 0=female, 1=male (ref) 0.449 0.183 to 1.106 0.082 0.706 0.381 to 1.309 0.269
Test χ² test P values df χ² test P values df
 Goodness-of-fit test
  Hosmer and Lemeshow test 5.41 0.71 8 5.27 0.73 8
*Poor HRQoL measured by EQ-5D questionnaire <0.6.
†Poor work ability measured by WAS<8.
HRQoL: Cox-Snell R²=0.12. Nagelkerke R²=0.21, n=238.
Work ability: Cox-Snell R²=0.11. Nagelkerke R²=0.16, n=235.
EQ-5D, EuroQol five-dimension; HRQoL, health-related quality of life; RCT, randomised clinical trial; SBT, StarT Back Tool; WAS, Work Ability 
Score. 
Table 2 Health-related quality of life and work ability at long-term follow-up—total population and stratified by SBT risk 
groups
Follow-up measure 
Total population
SBT risk group
P values
Low Medium High
n=238 n=103 n=107 n=28
Health-related quality of life; 
median (range) 0.80 (−0.14–1) 0.80 (0.09–1) 0.76 (0.09–1) 0.67 (−0.14–1) <0.001*
  EQ-5D† <0.6, n (%) 26 (11) 4 (4) 12 (11) 10 (36) <0.001§
Work ability‡; median (range) 8 (0–10) 9 (0–10) 8 (1–10) 7 (0–10) <0.001*
  WAS¶ <8, n (%) 78 (33) 23 (22) 38 (35) 17 (68) <0.001§
*Kruskal-Wallis test.
†EQ-5D scores, range −0.59–1.
‡Three missing from the high risk group (total population: n=235 and n=25 for the high risk group).
§Χ2 test for trend.
¶Where 0 equates to ‘completely unable to work’ and 10 equates to ‘work ability at its best’.
EQ-5D, EuroQol five-dimension; SBT, STarT Back Tool; WAS, Work Ability Score.
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on baseline and follow-up data. When recommending 
tools for use in primary care settings, preferably they 
should have been validated in large trials within this 
specific setting. However, as is the case with this study of 
the SBT, information from smaller studies is still of scien-
tific value. We accept that our study population (n=329) is 
unlikely to be representative of all individuals consulting 
primary care for acute/subacute BP and/or NP. However, 
even if they are a selected group of participants, we do not 
think that this will have substantially affected the psycho-
metric validation questions examined in this study.
The time to follow-up varied between patients in our 
study which may have influenced the results. The optimal 
time point for identifying patients at risk of developing 
persistent BP may vary and is a forum for discussion.49 In 
our study, two-third of the study population (n=160) were 
in the RCT and were followed up at a planned physio-
therapy visit at 12 months. For not RCT patients (n=78), 
the ambition was also to follow-up at 12 months but these 
patients were followed up with postal questionnaires and 
due to practical reasons there were a wider variation on 
the time for follow-up. This is of course a limitation, but 
did not have impact on the results in the regression anal-
yses. However, we had access to information about tenta-
tive confounding factors and we investigated several of 
these factors (age, sex, treatment and time to follow-up) 
that may have potentially influenced the prognostic 
ability of the SBT. In this study, we included both patients 
with NP and BP. Since this group of patients often have 
concurrent pain from the back or neck,11 we decided to 
not include this in the regression analysis. In another SBT 
non-stratified primary care setting where they studied 
different influences (care setting, episode duration and 
time to follow-up) on the prognostic ability of the SBT for 
disability outcomes50 they found that the only factor that 
modified the prognostic ability of the SBT risk groups was 
episode duration with SBT being less predictive in very 
acute patients (<2 weeks duration).
The ability of the SBT overall score to discriminate 
between patients with poor or good HRQoL and work 
ability differed slightly between the two outcomes with a 
slightly better discrimination for HRQoL (0.73) than for 
work ability (0.68). The AUC values are not very high, but 
still around 0.7, which is considered as acceptable.46 In a 
recent systematic review, Karran et al51 investigated how 
well prognostic screening instruments for BP, including 
the SBT, discriminate between patients who develop a poor 
outcome and those who do not.51 Prognostic screening 
tools tend to perform poorly at assigning higher risk 
scores to individuals who develop chronic pain compared 
with those who do not and they also tend to predict 
disability outcomes better than most other outcomes.51 
The discriminative performance of SBT for work ability 
outcomes in this study (AUC 0.68) was higher than for 
other prognostic tool’s reported abilities to discrimi-
nate pain outcomes (pooled AUC=0.59)51 and the SBT 
Figure 2 AUC and ROC curve for overall STarT Back Tool 
scores to discriminate between individuals with poor health-
related quality of life (EQ-5D<0.6) in long-term follow-up. 
Each point on the ROC curve has a corresponding cut-off 
value. The area under the ROC curve was 0.73. AUC, area 
under the curve; EQ-5D, Euroqol 5-dimension questionnaire; 
ROC, receiver operation characteristic. 
Figure 3 AUC and ROC curve for overall STarT Back Tool 
scores to discriminate between individuals with poor work 
ability (WAS<8) in long-term follow-up. Each point on the 
ROC curve has a corresponding cut-off value. The area under 
the ROC curve was 0.68. AUC, area under the curve; EQ-5D, 
Euroqol 5-dimension questionnaire; ROC, receiver operation 
characteristic. 
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discriminative performance for HRQoL outcomes in this 
study (AUC 0.73) was in line with the pooled disability 
predictive performance (pooled AUC=0.74). In compar-
ison to the original UK sample and a Danish sample in 
primary care, where participants had variable duration of 
BP and the primary outcomes were disability at 3 months 
follow-up,23 28 the predictive ability of the SBT in our study 
was not as strong as in the UK population (AUC 0.81) 
but similar to the Danish population (AUC 0.71). In our 
study, as in the Danish study, the physiotherapy treatment 
was not targeted to SBT risk groups and treatment was 
therefore likely to be heterogeneous. A variation of values 
are expected as the AUC (derived from the ROC curve: 
sensitivity/1−specificity), depends on the characteristics 
of the population and possible explanations might be 
cultural and differences in treatment. Another possible 
explanation in variation of AUC values may be that a ROC 
curve analysis requires dichotomisation of outcomes and 
the definitions of poor outcome may also have affected 
the results. The discriminative ability of the SBT risk 
groups to predict poor HRQoL and work ability outcome 
was affected of how the three risk groups were merged 
and dichotomised (low vs medium/high or low/medium 
vs high). Similar differences in discrimination were also 
found in the original study for disability outcomes.23 But 
regardless of which cut-off that was used, the results of 
the LRs indicate a slightly better discrimination of the 
SBT for poor HRQoL than for poor work ability and that 
the NPVs were consistently high for both outcomes which 
indicate a high probability that a good outcome is present 
when patients are classified as low risk. The proportion 
of patients with poor HRQoL and poor work ability was 
significantly higher in higher SBT risk groups at long-
term follow-up, but not all patients were correctly classi-
fied. When patients are misclassified as low risk they may 
be undertreated and when patients are misclassified as 
high risk they may be overtreated. It is important for clini-
cians to be aware of the potential of misclassification as 
costs for misclassification and overtreatment of patients 
with a good prognosis can be high24 and also detrimental 
in patients with acute BP.52
The EQ-5D was applied to measure HRQoL because it 
has been found to have good prediction of return to work 
and the cut-off ≥0.6 on EQ-5D has been proposed to be 
a limit for having sufficient capacity to work for patients 
with BP and NP.39 Another cut-off has been used in a study 
of patients with musculoskeletal pain taking part in a 
national rehabilitation programme in Sweden where ≥0.5 
on EQ-5D at start showed reduced sick leave days after 
the rehabilitation.53 Our population had a median EQ-5D 
score of 0.80, which is just below the mean scores for a 
Swedish normal population (0.84).54 The fact that our 
sample included patients at an early stage of their pain 
(acute/subacute) with no or short time of sick leave may 
have influenced the high level of HRQoL in our study 
sample. To measure work ability, we used the WAS which 
is the first item in the WAI, a widely used questionnaire 
for measuring the health and functional capacity dimen-
sion of work ability.41 The cut-off (WAS<8/≥8) chosen in 
this study represents poor or moderate (poor) and good/
excellent (good) work ability based on the same categori-
sation as for the whole WAI.42 The WAS has shown to 
be a good alternative to the whole WAI,43 even though 
the whole WAI is superior compared with its individual 
items.55
SBTs concurrent validity has earlier been studied for 
patients with BP and/or NP26 and a modified SBT have 
been tested to predict physical health outcome, using the 
SF-3656 but this was the first time the predictive validity 
of the SBT was studied for the outcomes of HRQoL 
and work ability for individuals with both BP and NP. 
Therefore, this study widens the usefulness of the SBT 
compared with earlier studies.23 57–60 There is also need 
for short questionnaires that are easy to use in clinical to 
distribute and interpret, especially in primary care. The 
SBT is primarily designed as a ‘stratified care tool’, which 
involves targeting treatment to subgroups of patients 
based on their key characteristics61 but in this study, we 
wanted to study if the SBT could predict the important 
outcomes HRQoL and work ability when applied in an 
RCT of NP and BP. In this study, the physiotherapists 
did not target treatment based on SBT. However, we 
accept that some of the constructs within the SBT may 
Table 4 Discriminative ability of the SBT risk group cut-offs (L/M and M/H) to predict poor HRQoL and poor work ability in 
long-term follow-up
Subgroups
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
LR+
(95% CI)
LR−
(95% CI)
HRQoL (EQ-5D<0.6)
  L vs M/H 84.6 46.7 16.3 96.1 1.59 (1.29 to 1.95) 0.33 (0.13 to 0.82)
  L/M vs H 38.5 91.5 35.7 92.4 4.53 (2.35 to 8.74) 0.67 (0.49 to 0.91)
Work ability (WAS<8)
  L vs M/H 70.5 51.0 41.7 77.7 1.44 (1.16 to 1.78) 0.58 (0.40 to 0.84)
  L/M vs H 21.8 94.9 68.0 71.0 4.28 (1.93 to 9.47) 0.82 (0.73 to 0.93)
EQ-5D, EuroQol five-dimension; H, high; HRQoL, health-related quality of life; L, low; LR+, positive likelihood ratio; LR−, negative likelihood 
ratio; M, medium; NPV, negative predictive value; PPV, positive predictive value; SBT, STarT Back Tool; WAS, Work Ability Score.
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have been addressed by the intervention provided, which 
may have affected SBTs ability to predict the above-men-
tioned outcomes. The results of this study suggest that 
the SBT can be used as a prognostic tool in primary care 
for subgroup identification of acute/subacute BP and/
or NP patients at risk of poor long-term HRQoL and/or 
work ability outcome. This information about important 
risk factors may help clinicians in primary care to develop 
personalised treatment strategies which are a priority 
in research.62 Future studies are required to investigate 
whether the implementation of screening together with 
matched treatment pathways have an effect on HRQoL 
and work ability outcomes for these patients.
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